Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
| Autor: | Gerasimos Konidaris, Divina Glah, Barrie Chubb, Phil McEwan, Melanie J. Davies |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Insulin degludec
Blood Glucose medicine.medical_specialty Cost effectiveness medicine.medical_treatment Cost-Benefit Analysis Insulins 030209 endocrinology & metabolism Type 2 diabetes 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine medicine Humans Hypoglycemic Agents 030212 general & internal medicine Pharmacology Glycated Hemoglobin Liraglutide Insulin glargine business.industry Health Policy Insulin Public Health Environmental and Occupational Health Type 2 Diabetes Mellitus medicine.disease Hypoglycemia United Kingdom Insulin Long-Acting Drug Combinations Endocrinology Models Economic Diabetes Mellitus Type 2 Quality-Adjusted Life Years business medicine.drug |
| Zdroj: | PharmacoEconomics. 34(9) |
| ISSN: | 1179-2027 |
| Popis: | Once-daily insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon like peptide-1 receptor agonist combined in one delivery device. Our aim was to investigate the cost effectiveness of IDegLira vs. basal insulin intensification therapies for patients with type 2 diabetes mellitus uncontrolled on basal insulin (glycosylated haemoglobin; HbA1c >7.5 %; 58 mmol/mol) in a UK setting. Baseline cohort and clinical parameters were sourced from a pooled analysis comparing IDegLira with basal insulin plus liraglutide and basal-bolus therapy, and from the DUAL™ V trial comparing IDegLira with up-titrated insulin glargine (IGlar; Lantus®). The CORE Diabetes Model simulated lifetime costs and outcomes with IDegLira vs. these comparators from a UK healthcare payers’ perspective. All costs were expressed in 2015 GBP. Sensitivity analyses were performed to assess the impact of key parameters in the model. Treatment with IDegLira resulted in mean increases in quality-adjusted life-years (QALYs) of 0.12, 0.41 and 0.24 vs. basal insulin plus liraglutide, basal-bolus therapy and up-titrated IGlar, respectively. IDegLira was associated with lower costs of £971 and £1698 vs. basal insulin plus liraglutide and basal-bolus therapy, respectively, and increased costs of £1441 vs. up-titrated IGlar. IDegLira was dominant, i.e., both more effective and less costly vs. basal insulin plus liraglutide and basal-bolus therapy, and highly cost effective vs. up-titrated IGlar with an incremental cost-effectiveness ratio of £6090/QALY gained. Once-daily IDegLira may be considered a cost-effective treatment option for prescribers, to improve glycaemic control for type 2 diabetes patients uncontrolled on basal insulin without an increased risk of hypoglycaemia or weight gain, and without adding to their injection burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink